AngioDynamics enters the week with a notable gap between where the stock trades and where analysts think it belongs — and the market's short positioning has started to quietly reflect that divergence.
Short sellers have been trimming exposure. SI % FF fell from around 5.97% in late April to 5.73% now, a steady bleed that represents roughly a 3% reduction on the week. The move follows an 11% monthly price gain to $10.90 — a rally that has made the short trade progressively more uncomfortable. Days to cover remain above five based on FINRA's fortnightly data, so the position is not small, but the direction of travel is clearly toward de-risking rather than escalation.
The borrow market is consistent with that message. Cost to borrow is nearly negligible at just 0.30%, down sharply from above 0.55% in late April and early May. Availability is wide open — utilization running near 5% against a 52-week high of 15.6% means there is ample lending supply, and no mechanical pressure on anyone who wants to cover. The put/call ratio, at 1.95, looks elevated in isolation but is actually fractionally below its 20-day average of 2.06. Options positioning has been persistently defensive on this name — the 52-week PCR high of 2.47 was hit in late April — but the current reading represents a slight easing of that caution, not a new extreme.
The Street's bull case rests on two pillars: Auryon's expanding customer base driving better average selling prices, and a margin expansion path toward 52.5% gross margins as the company shifts its revenue mix toward higher-value Med-Tech. Analysts are unanimously bullish — all four covering the stock carry Buy ratings — and the consensus mean target of $18.00 implies more than 65% upside to the current price. The most recent action, from Canaccord Genuity in early April, trimmed its target from $18 to $16 while maintaining Buy — a signal of recalibration after the April earnings shock rather than a change in conviction. That note is now 37 days old, so the analyst picture has been static since. The bear case is more concrete: estimated tariff headwinds of $4–6 million, rising raw material costs pressuring H2 fiscal 2026 inventory, and a company still running net losses. The EV/EBITDA multiple of 34x reflects a growth premium that demands execution.
The April 2 earnings print is the clearest recent scar on this story. The stock fell 17.6% on the day and extended losses to -15.5% over the following five sessions — a sharp response that likely accelerated the short rebuild visible in late-April data, with SI % FF climbing from around 5.24% on April 23 to nearly 5.97% by late April before the current retreat. The company beat on EPS surprise — ranked in the 88th percentile historically — which creates an interesting disconnect: the market punished the print, but the company's history of exceeding estimates has been strong.
Institutional ownership adds a stabilising backdrop. BlackRock reported adding nearly 386,000 shares to reach 9.3% ownership as of April 30. State Street added 316,000 shares in the same period. Those are not activist positions, but concurrent buying from two of the largest passive managers suggests index mechanics are working in the stock's favour alongside any active theses. Point72, with 6.8% of shares as of year-end, provides a higher-conviction name in the holder list.
The next scheduled earnings event is July 13. Between now and then, the watch items are whether the short-base continues its gradual unwinding as the stock consolidates near $10.90, and whether management provides any update on the tariff headwind quantification that spooked the market in April.
See the live data behind this article on ORTEX.
Open ANGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
